Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Medtronic
Baxter
Moodys
McKesson
Harvard Business School
Dow

Last Updated: November 18, 2019

DrugPatentWatch Database Preview

Levomilnacipran hydrochloride - Generic Drug Details

See Plans and Pricing

« Back to Dashboard

What are the generic drug sources for levomilnacipran hydrochloride and what is the scope of freedom to operate?

Levomilnacipran hydrochloride is the generic ingredient in two branded drugs marketed by Allergan Sales Llc and Amneal Pharms Co, and is included in two NDAs. There are three patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Levomilnacipran hydrochloride has fifty-four patent family members in twenty-seven countries.

There are eleven drug master file entries for levomilnacipran hydrochloride. Two suppliers are listed for this compound.

Recent Clinical Trials for levomilnacipran hydrochloride

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
AllerganPhase 3
AllerganPhase 4
University of OttawaPhase 4

See all levomilnacipran hydrochloride clinical trials

Recent Litigation for levomilnacipran hydrochloride

Identify potential future generic entrants

District Court Litigation
Case NameDate
ALLERGAN SALES, LLC v. MICRO LABS LTD.2019-04-12
FOREST LABORATORIES, LLC v. AUROBINDO PHARMA USA, INC.2017-11-15
FOREST LABORATORIES, LLC v. AMNEAL PHARMACEUTICALS LLC2017-11-15

See all levomilnacipran hydrochloride litigation

Pharmacology for levomilnacipran hydrochloride
Synonyms for levomilnacipran hydrochloride
(1R,2S)-rel-2-(Aminomethyl)-N,N-diethyl-1-phenylcyclopropanecarboxamide hydrochloride
(1R,2S)-rel-2-(Aminomethyl)-N,N-diethyl-1-phenylcyclopropanecarboxamide monohydrochloride
(1S-cis)-Milnacipran Hydrochloride
(1S,2R)-2-(aminomethyl)-N,N-diethyl-1-phenylcyclopropane-1-carboxamide hydrochloride
(1S,2R)-2-(aminomethyl)-N,N-diethyl-1-phenylcyclopropane-1-carboxamide;hydrochloride
(1S,2R)-2-(Aminomethyl)-N,N-diethyl-1-phenylcyclopropanecarboxamide Hydrochloride
(1S,2R)-Milnacipran Hydrochloride
101152-94-7
152M947
175131-60-9
371U2ZK31U
AC1OCEN6
AK481450
AKOS025311514
API0003393
AS-12868
AT-28508
C15H22N2O.HCl
CCG-231710
CHEMBL2105732
cis-(+)-Milnacipran Hydrochloride
cis-2-(Aminomethyl)-N,N-diethyl-1-phenylcyclopropanecarboxamide Hydrochloride
CS-4972
D10133
Dalcipran
F 2695 hydrochloride
F-2207
Fetzima
Fetzima (TN)
HY-B0168B
Ixel
J10386
Joncia
K-0218
Levomilnacipran HCl
Levomilnacipran hydrochloride (USAN)
Levomilnacipran hydrochloride [USAN]
M2133
MFCD00901293
Midalcipran hydrochloride
Milnacipran ((1S-cis) hydrochloride)
Milnacipran HCl
Milnacipran hydrochloride
Milnacipran Hydrochloride 1.0 mg/ml in Methanol (as free base)
MolPort-019-939-251
rac-Milnacipran Hydrochloride
Savella
SB17448
SCHEMBL1148742
TN-912
Toledomin
UNII-371U2ZK31U
UNII-RNZ43O5WW5 component XNCDYJFPRPDERF-NQQJLSKUSA-N
Paragraph IV (Patent) Challenges for LEVOMILNACIPRAN HYDROCHLORIDE
Tradename Dosage Ingredient NDA Submissiondate
FETZIMA CAPSULE, EXTENDED RELEASE;ORAL levomilnacipran hydrochloride 204168 2017-07-25

US Patents and Regulatory Information for levomilnacipran hydrochloride

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Allergan Sales Llc FETZIMA levomilnacipran hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 204168-001 Jul 25, 2013 RX Yes No   Start Trial   Start Trial   Start Trial
Allergan Sales Llc FETZIMA levomilnacipran hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 204168-002 Jul 25, 2013 RX Yes No   Start Trial   Start Trial   Start Trial
Allergan Sales Llc FETZIMA levomilnacipran hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 204168-001 Jul 25, 2013 RX Yes No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Boehringer Ingelheim
Moodys
Mallinckrodt
Dow
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.